Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Lasofoxifene in combination with abemaciclib|DRUG: Fulvestrant in combination with abemaciclib
Sponsor: Sermonix Pharmaceuticals Inc.